# US 11,077,150 B2 · Methods and compositions for treatment of eye conditions > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,077,150 B2 - Document ID: US11077150B2 - Status: Granted - Kind: B2 - Application number: 16/595,374 - Filed: 2019-10-07 - Published: 2020-04-09 - Granted: 2021-08-03 - Earliest claimed: 2018-10-09 - Applicants: Travis Castro; Tricia Scribner; Massoumeh Kharazmi - Inventors: Travis Castro; Tricia Scribner; Mohammad Ali Kharazmi - Web page: https://patentgrep.com/patent/US11077150B2 ## CPC - A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells - A61K 9/0048: {Eye, e.g. artificial tears} - A61K 9/5123: {Organic compounds, e.g. fats, sugars} - A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)} - A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin} - A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} - A61K 31/4164: 1,3-Diazoles - A61K 31/4172: Imidazole-alkanecarboxylic acids, e.g. histidine - A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol} - A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells - A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells - A61K 38/05: Dipeptides - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 27/02: Ophthalmic agents - A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention includes compositions and methods of administering the compositions to improve the condition of damaged eye tissues. The compositions include cannabinoids such as cannabidiol and one or more of human stem cell products, lutein, and N-acetyl carnosine. The compositions include components that are encapsulated and may include a mixture of separately encapsulated materials. The methods include administering the compositions as drops to an affected eye. ## Claims ### Claim 1 An eye treatment composition comprising: a first plurality of nanocapsules; a plurality of microcapsules; a cannabinoid dispersed in the first plurality of nanocapsules; N-acetyl carnosine dispersed in the plurality of microcapsules; an aqueous carrier, the first plurality of nanocapsules and the plurality of microcapsules suspended in an aqueous carrier; and lutein dispersed in a second plurality of nanocapsules. ### Claim 2 (depends on 1) A method of treating an eye condition comprising applying an effective amount of the eye treatment composition of claim 1 to an affected eye. ### Claim 3 (depends on 1) The eye treatment composition of claim 1, wherein the first plurality of nanocapsules has a median size in the range of 50 to 250 nm, and wherein the plurality of microcapsules has a median size in the range of 500 nm to 5 μm. ### Claim 4 (depends on 1) The eye treatment composition of claim 1, wherein the first plurality of nanocapsules further contains a lutein co-dispersed with the cannabinoid. ### Claim 5 (depends on 1) The eye treatment composition of claim 1, wherein the aqueous carrier includes a vasoconstrictor and a lubricant. ### Claim 6 (depends on 5) The eye treatment composition of claim 5, wherein the lubricant has one or more of glycerol, polyethylene glycol 400, hydroxypropyl methylcellulose, or propylene glycol. ### Claim 7 (depends on 1) The eye treatment composition of claim 1, wherein the cannabinoid includes cannabidiol (CBD) or tetrahydrocannabinol (THC). ### Claim 8 An eye treatment composition comprising: a first plurality of nanocapsules including a cannabinoid dispersed in the first plurality of nanocapsules; a second plurality of nanocapsules including lutein dispersed in the second plurality of nanocapsules; and an aqueous carrier, the first plurality of nanocapsules and the second plurality of nanocapsules suspended in the aqueous carrier. ### Claim 9 (depends on 8) The eye treatment composition of claim 8, wherein the first plurality of nanocapsules has a median size in the range of 50 to 250 nm. ### Claim 10 (depends on 8) The eye treatment composition of claim 8, wherein the cannabinoid includes cannabidiol (CBD) or tetrahydrocannabinol (THC). ### Claim 11 (depends on 8) The eye treatment composition of claim 8, further comprising an aqueous antioxidant mixed with the aqueous carrier. ### Claim 12 (depends on 8) The eye treatment composition of claim 8, further comprising a lubricant or a vasoconstrictor mixed with the aqueous carrier. ### Claim 13 (depends on 8) The eye treatment composition of claim 8, further comprising a stem cell conditioned medium mixed with the aqueous carrier. ### Claim 14 (depends on 8) The eye treatment composition of claim 8, further comprising a plurality of microcapsules encapsulating a conditioned medium, wherein the conditioned medium is derived from a culture of one or more of a human hematopoietic stem cell, a human endothelium-derived stem cell, a human adipose-derived stem cell, a human tooth mesenchyme-derived stem cell, or a human placenta-derived stem cell. ### Claim 15 (depends on 14) The eye treatment composition of claim 14, wherein the aqueous carrier includes a lubricant. ### Claim 16 (depends on 15) The eye treatment composition of claim 15, wherein the aqueous carrier includes a vasoconstrictor. ### Claim 17 (depends on 16) The eye treatment composition of claim 16, wherein the first plurality of nanocapsules further contains lutein co-dispersed with the cannabinoid. ### Claim 18 (depends on 17) The eye treatment composition of claim 17, wherein the aqueous carrier includes N-acetyl carnosine.